GlycoMimetics Statistics
Total Valuation
GlycoMimetics has a market cap or net worth of $17.25 million. The enterprise value is $2.82 million.
Important Dates
The last earnings date was Wednesday, November 13, 2024, after market close.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
GlycoMimetics has 64.48 million shares outstanding. The number of shares has increased by 6.56% in one year.
| Current Share Class | 64.48M |
| Shares Outstanding | 64.48M |
| Shares Change (YoY) | +6.56% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 2.87% |
| Owned by Institutions (%) | 12.94% |
| Float | 43.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.49 |
| P/TBV Ratio | 1.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 282.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.62, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.62 |
| Quick Ratio | 3.34 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -137.20% and return on invested capital (ROIC) is -77.67%.
| Return on Equity (ROE) | -137.20% |
| Return on Assets (ROA) | -66.74% |
| Return on Capital (ROIC) | -77.67% |
| Revenue Per Employee | $286 |
| Profits Per Employee | -$1.14M |
| Employee Count | 35 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.10% in the last 52 weeks. The beta is 1.83, so GlycoMimetics's price volatility has been higher than the market average.
| Beta (5Y) | 1.83 |
| 52-Week Price Change | -91.10% |
| 50-Day Moving Average | 0.30 |
| 200-Day Moving Average | 0.44 |
| Relative Strength Index (RSI) | 50.27 |
| Average Volume (20 Days) | 455,331 |
Short Selling Information
The latest short interest is 2.17 million, so 3.37% of the outstanding shares have been sold short.
| Short Interest | 2.17M |
| Short Previous Month | 2.23M |
| Short % of Shares Out | 3.37% |
| Short % of Float | 5.05% |
| Short Ratio (days to cover) | 1.07 |
Income Statement
In the last 12 months, GlycoMimetics had revenue of $10,000 and -$39.74 million in losses. Loss per share was -$0.62.
| Revenue | 10,000 |
| Gross Profit | 10,000 |
| Operating Income | -36.78M |
| Pretax Income | -39.11M |
| Net Income | -39.74M |
| EBITDA | -36.73M |
| EBIT | -36.78M |
| Loss Per Share | -$0.62 |
Full Income StatementBalance Sheet
The company has $14.39 million in cash and $262,133 in debt, giving a net cash position of $14.13 million or $0.22 per share.
| Cash & Cash Equivalents | 14.39M |
| Total Debt | 262,133 |
| Net Cash | 14.13M |
| Net Cash Per Share | $0.22 |
| Equity (Book Value) | 11.38M |
| Book Value Per Share | 0.18 |
| Working Capital | 11.32M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$35.01 million and capital expenditures -$10,773, giving a free cash flow of -$35.02 million.
| Operating Cash Flow | -35.01M |
| Capital Expenditures | -10,773 |
| Free Cash Flow | -35.02M |
| FCF Per Share | -$0.54 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -367,847.59% |
| Pretax Margin | -397,350.46% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |